For the year ending 2025-12-31, STOK made $184,420K in revenue. -$6,191K in net income. Net profit margin of -3.36%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 184,420 | |||
| Research and development | 137,922 | |||
| Sales, general and administrative | 67,088 | |||
| Total operating expenses | 205,010 | |||
| Loss from operations | -20,590 | |||
| Interest income (expense), net | 13,756 | |||
| Other income (expense), net | -51 | |||
| Total other income (expense) | 13,705 | |||
| Net loss | -6,885 | |||
| Unrealized gain (loss) on marketable securities | 694 | |||
| Total other comprehensive gain (loss) | 694 | |||
| Comprehensive loss | -6,191 | |||
| Basic EPS | -0.12 | |||
| Diluted EPS | -0.12 | |||
| Basic Average Shares | 59,219,184 | |||
| Diluted Average Shares | 59,219,184 | |||
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)